Navigation Links
500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
Date:5/28/2009

BERLIN, May 28 /PRNewswire/ -- The 500th patient was supported with the Berlin Heart EXCOR(R) Pediatric Ventricular Assist Device (also known as the "Berlin Heart") since the first implantation of the device in 1990. The patient, an 11-month-old girl, received the device at the Children's Memorial Hospital in Chicago and has been successfully transplanted in the meantime.

Alejandra had been diagnosed a few weeks after birth with left ventricular non compaction and dilative cardiomyopathy, a disease that causes the heart muscle to enlarge and weaken. From six months of age, she received medications for her heart disease, but as she progressively worsened, she had to be placed on the waiting list for a donor heart. She presented to Dr. Elfriede Pahl, medical director of heart transplantation at Children's Memorial Hospital, with a respiratory infection and required mechanical ventilation.

Alejandra was placed on ECMO, a modified version of a heart-lung machine, on 2 January 2009, but rapidly deteriorated. "She was difficult to support on ECMO with a good deal of bleeding and relatively poor systemic perfusion," recalls Dr. Jeffrey Gossett, Alejandra's cardiologist. "As a result we needed to continue paralysis and were unable to feed her well."

By the time she received the Berlin Heart EXCOR Pediatric VAD, she had spent 38 days on mechanical ventilation and three days on ECMO. Alejandra's mother recalls, "We were devastated and very anxious. We had to hope for a miracle to help Alejandra."

    Full story under:
http://www.berlinheart.com/500th_EXCOR_Pediatric_Patient_full_story.pdf

Pictures available.

About EXCOR(R) Pediatric

The EXCOR Pediatric Ventricular Assist Device is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. EXCOR Pediatric has been used in more than 500 pediatric patients worldwide ranging from newborns with 2.2 kg body weight to teenagers. EXCOR is currently under clinical investigation for pediatric patients in USA.

About Berlin Heart

Berlin Heart GmbH is the only company worldwide that develops, produces, and distributes implantable and external ventricular assist devices (also called mechanical heart support systems) for patients of every age and body size. The company is market leader in Germany and Europe.

The company also manufactures the implantable left ventricular assist device INCOR(R), which has been designed for long-term application in adult patients. The longest the device has supported a patient so far is more than five and a half years and ongoing. INCOR is not FDA approved, but widely used in Europe.

    Contact:

    Linda Buerk
    Manager Marketing & PR
    Phone: +49(0)30-8187-2650
    Mobile: +49(0)173-629-0803
    buerk@berlinheart.de



'/>"/>
SOURCE Berlin Heart GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Plexon Inc Delivers 500th "Harvey Box" : 25 Years of Neural Data Acquisition and Analysis Leads to 500th System Sale
2. Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation
3. SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System
4. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
5. Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22
6. VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
7. Adipose-derived Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Groups, Entest BioMedical Inc. Researcher
8. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
9. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
10. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
11. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... SWB805 MultiMountTM weigh modules. These weigh modules are designed according to European ... Foundation (NSF). , As fully integrated weighing solutions, SWB805 MultiMount weigh modules ...
(Date:3/27/2017)... 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular ... detection of foodborne pathogens,  today announced that Mary Duseau ... 2017 Convention on March 29 at 9:50am ET. The conference ... About Roka Bioscience ... Roka Bioscience is a molecular ...
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is ... (CTC) conference presented by The Conference Forum in Boston on April 3-4, 2017. The ... drive improved clinical trial outcomes and bring them closer to the patient. Clinical Trial ...
Breaking Biology Technology:
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
Breaking Biology News(10 mins):